From £6.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Still loving GlaxoSmithKline as Unilever bid emerges

By Chris Bailey of Financial Orbit | Sunday 16 January 2022


Disclosure: I own shares in one or more of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


I was already excited about the upcoming week, predominately because a bunch of interesting companies are giving us an update on Monday, Tuesday, Wednesday, Thursday, and Friday.  So maybe an existing holding does well or maybe I get an opportunity to consider a new angle.  One stock I am going to be watching closely on Monday morning is GlaxoSmithKline (GSK) as I read that ‘Unilever(ULVR) makes £50 billion bid for GSK’s consumer business’. 

Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

 

CTAI

Catenai – monster dilution

Time left: 08:23:19